SCHEDULE 13D/A: SCHEDULE 13D/A – Description

• Post author:Allogene Therapeutics SEC Filings
• Post published:September 30, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13D/A: SCHEDULE 13D/A – Description

8-K: Report of unscheduled material events or corporate event

• Post author:Allogene Therapeutics SEC Filings
• Post published:September 2, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

4: Statement of changes in beneficial ownership of securities

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 25, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock.

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 21, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock.

EFFECT: EFFECT

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 21, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue ReadingEFFECT: EFFECT

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 14, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description

S-3: Simplified registration form

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 12, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue ReadingS-3: Simplified registration form

10-Q: Quarterly report which provides a continuing view of a company’s financial position

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 12, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company’s financial position

8-K: Report of unscheduled material events or corporate event

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 12, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

SCHEDULE 13G/A: SCHEDULE 13G/A – Description

• Post author:Allogene Therapeutics SEC Filings
• Post published:August 7, 2026
• Post category:Uncategorized

Allogene Therapeutics, Inc.

Continue ReadingSCHEDULE 13G/A: SCHEDULE 13G/A – Description